Clinical trials: Neurological; Disorder, Nervous System
Major Depressive Disorder
Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression
The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)
- Trial name
- NCT06419608
- Testing
- BHV-7000
- Where
- 62 sites in United States
- Volunteers
- 336 people
- Sponsor
- Biohaven Therapeutics Ltd.
Oncology, Taste, Altered
Assessment of ONS-flavour Preference in Cancer Patients With and Without Taste Alterations
A single arm intervention study examining ONS-flavour preference in cancer patients with and without taste alterations
- Trial name
- PREFER (NCT05518825)
- Testing
- Fortimel/Nutridrink Compact Protein
- Where
- Netherlands
- Volunteers
- 64 people
- Sponsor
- Nutricia Research
Acquired Brain Injury, Stroke
Computerized Attention Training for Individuals With Acquired Brain Injury
Problems with attention are a common and debilitating consequence of brain injury. Studies show that poor attention is the number one predictor of poor cognitive functioning one year post-injury.
- Conditions
- Acquired Brain Injury, Stroke, Hemispatial Neglect
- Trial name
- NCT01641432
- Testing
- Tonic and Phasic Attention Training, Active Comparator
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Posit Science Corporation
Noise Exposure, Noise-induced Hearing Loss
Non-Invasive System to Deliver Therapeutic Hypothermia for Protection Against Noise-Induced Hearing Loss
The goal of this interventional clinical study is to investigate the use of mild therapeutic hypothermia devices for preservation of sensory structures in the cochlea after noise exposure. The main aims of the study are: 1.
- Conditions
- Noise Exposure, Noise-induced Hearing Loss, Noise; Adverse Effect, Mild Therapeutic Hypothermia
- Trial name
- NCT06729632
- Testing
- Cold pack-delivered mild therapeutic hypothermia
- Where
- United States
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Restorear Devices LLC
Low Back Pain
A Study of Tanezumab in Adults With Chronic Low Back Pain
The purpose of this study is to evaluate the efficacy and safety of multiple doses of tanezumab administered every 8 weeks in treating chronic low back pain.
- Trial name
- NCT00876187
- Testing
- Tanezumab 20 mg IV, Tanezumab 10 mg IV, Tanezumab 5 mg IV
- Where
- 135 sites in United States
- Volunteers
- 1,359 people
- Sponsor
- Pfizer
Migraine Headache
An Evaluation Of The Efficacy And Safety Of Donepezil Hydrochloride (E2020) In Migraine Prophylaxis
The purpose of this extension study was to evaluate the safety and efficacy of donepezil hydrochloride after extended use in migraine prophylaxis. Efficacy will continue to be evaluated.
- Trial name
- NCT01146509
- Testing
- Aricept (donepezil hydrochloride)
- Where
- 4 sites in United States
- Volunteers
- 89 people
- Sponsor
- Eisai Inc.
Parkinson Disease, Dyskinesia, Drug-Induced
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day).
- Conditions
- Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
- Trial name
- NCT04857359
- Testing
- Dipraglurant
- Where
- 41 sites in United States
- Volunteers
- 25 people
- Sponsor
- Addex Pharma S.A.
Hearing Loss, Sensorineural, Hearing Loss
Speech Intelligibility in Quiet and Noise for New vs. Legacy Hearing Aids
This clinical investigation is designed to compare audiological performance (i.e., measurements of sound quality and speech understanding) between Starkey's new receiver-in-canal device and a commercially available legacy…
- Trial name
- NCT05101083
- Testing
- New Receiver-in-Canal Device, Legacy Receiver-in-Canal Device
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Starkey Laboratories, Inc
Muscle Spasticity
Spasticity Registry Evaluating Epidemiology, Treatment Patterns and Clinical Needs
This study will examine the epidemiology (incidence and control of a disease), burden, clinical need, and treatment patterns of spasticity in patients with a diagnosis of Cerebral Palsy (CP), Multiple Sclerosis (MS), Stroke…
- Trial name
- STRETCh (NCT02145650)
- Testing
- No Intervention
- Where
- United States
- Sponsor
- Allergan
Sleep Disorder
A Clinical Study on the Improvement of Sleep Quality, Skin Condition and Life Status After Taking Sleep Aid Drinks
The main objective of the study is to observe changes in the subjects' sleep quality, skin condition and life status after 4 weeks of using a sleep aid drink (AOXMED Poria γ-aminobutyric acid drink).
- Trial name
- NCT05908903
- Testing
- Drinks with active ingredients such as poria and GABA
- Where
- China
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Botanee Group Co., Ltd.
Choroidal Neovascularization (CNV)
Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.
This study was conducted to evaluate the efficacy and safety of 0.5 mg ranibizumab in adult and adolescent patients with visual impairment due to choridal neovascularization (CNV).
- Trial name
- NCT01840410
- Testing
- Ranibizumab
- Where
- 59 sites in Australia, Canada and 19 more
- Volunteers
- 183 people
- Sponsor
- Novartis Pharmaceuticals
Pain, Sleep Disturbance
Radicle ACES: A Study of Commercially Available CBD Used in the Real-world Setting
A randomized, open-label study of commercially available, orally ingestible, Cannabidiol (CBD) products used in the real-world setting for pain, sleep, and anxiety.
- Conditions
- Pain, Sleep Disturbance, Anxiety
- Trial name
- RWE-ACES (NCT05003882)
- Testing
- Commercially available, orally ingestible CBD product
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Radicle Science
Alzheimer's Disease
A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to compare the effectiveness and safety of 2 years of treatment with galantamine as compared with placebo of patients who have mild to moderately severe Alzheimer's disease (AD).
- Trial name
- NCT00679627
- Testing
- Galantamine
- Where
- 95 sites in Czechia, Estonia and 10 more
- Volunteers
- 2,051 people
- Sponsor
- Janssen Research & Development, LLC
Seizures Associated With EMAS
Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures
The primary aim of Part A of the study to assess the efficacy and tolerability of GWP42003-P compared to placebo as an adjunctive treatment for children with Epilepsy with myoclonic-atonic seizures (EMAS) -associated seizures.
- Trial name
- NCT05288283
- Testing
- GWP42003-P
- Where
- 14 sites in United States, Italy
- Volunteers
- 3 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis, Muscle Spasticity
Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity.
This study is being conducted to compare the impact of somnolence (sleepiness) on cognition (awareness) as well as the safety and effectiveness of tizanidine hydrochloride capsules versus Zanaflex® (tizanidine hydrochloride…
- Conditions
- Multiple Sclerosis, Muscle Spasticity, Spinal Cord Injury, Stroke
- Trial name
- NCT00047580
- Testing
- tizanidine hydrochloride capsule
- Where
- 16 sites in United States
- Volunteers
- 120 people
- Sponsor
- Elan Pharmaceuticals
Pediatric Migraine
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
- Trial name
- NCT04649242
- Testing
- Rimegepant/BHV3000
- Where
- 246 sites in United States, Canada and 7 more
- Volunteers
- 2,100 people
- Sponsor
- Pfizer
Myotonic Dystrophy Type 1, DM1
Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy…
- Conditions
- Myotonic Dystrophy Type 1, DM1, Myotonic Dystrophy, Myotonia
- Trial name
- HARBOR-OLE (NCT07008469)
- Testing
- Del-desiran (AOC 1001)
- Where
- 35 sites in United States, Canada and 8 more
- Volunteers
- 199 people
- Sponsor
- Avidity Biosciences, Inc.
Seizures
Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures
The purpose of the study is to evaluate the effectiveness and safety of adjunctive RWJ-333369 at a dose of 200 or 400 mg/day in comparison with placebo in Korean and Japanese partial epilepsy patients who have poor seizure…
- Trial name
- NCT00697762
- Testing
- RWJ-333369
- Volunteers
- 56 people
- Sponsor
- SK Life Science, Inc.
Refractory Partial Seizures
To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
The purpose of this study is to evaluate the efficacy, safety and tolerability of perampanel when given as an adjunctive therapy in subjects with refractory partial seizures.
- Trial name
- NCT00699582
- Testing
- E2007 (perampanel)
- Where
- 92 sites in United States, Austria and 12 more
- Volunteers
- 389 people
- Sponsor
- Eisai Inc.
Hearing Loss, Sensorineural
Evaluation of the Efficacy and Safety of the Sullivan Cochlear Implant.
The study will be conducted as a prospective, single center, repeat measure, single-arm, open label clinical study
- Trial name
- NCT07018882
- Testing
- Sullivan
- Volunteers
- 25 people
- Sponsor
- Todoc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.